Abstract: Described herein are preserved formulations of insulin-Fc fusions. The formulations include insulin-Fc fusions having prolonged pharmacokinetic and pharmacodynamic profiles sufficient for once weekly administration in the treatment of diabetes and are sufficiently stable to allow for storage and use without unacceptable loss of chemical or physical stability.
| # | Name | Date |
|---|---|---|
| 1 | 202417033206-STATEMENT OF UNDERTAKING (FORM 3) [26-04-2024(online)].pdf | 2024-04-26 |
| 2 | 202417033206-Sequence Listing in txt [26-04-2024(online)].txt | 2024-04-26 |
| 3 | 202417033206-Sequence Listing in PDF [26-04-2024(online)].pdf | 2024-04-26 |
| 4 | 202417033206-REQUEST FOR EXAMINATION (FORM-18) [26-04-2024(online)].pdf | 2024-04-26 |
| 5 | 202417033206-PRIORITY DOCUMENTS [26-04-2024(online)].pdf | 2024-04-26 |
| 6 | 202417033206-POWER OF AUTHORITY [26-04-2024(online)].pdf | 2024-04-26 |
| 7 | 202417033206-FORM 18 [26-04-2024(online)].pdf | 2024-04-26 |
| 8 | 202417033206-FORM 1 [26-04-2024(online)].pdf | 2024-04-26 |
| 9 | 202417033206-DECLARATION OF INVENTORSHIP (FORM 5) [26-04-2024(online)].pdf | 2024-04-26 |
| 10 | 202417033206-COMPLETE SPECIFICATION [26-04-2024(online)].pdf | 2024-04-26 |
| 11 | 202417033206-Proof of Right [02-05-2024(online)].pdf | 2024-05-02 |
| 12 | 202417033206-FORM-26 [02-05-2024(online)].pdf | 2024-05-02 |
| 13 | 202417033206-FORM 3 [23-10-2024(online)].pdf | 2024-10-23 |
| 14 | 202417033206-MARKED COPIES OF AMENDEMENTS [24-02-2025(online)].pdf | 2025-02-24 |
| 15 | 202417033206-FORM 13 [24-02-2025(online)].pdf | 2025-02-24 |
| 16 | 202417033206-AMMENDED DOCUMENTS [24-02-2025(online)].pdf | 2025-02-24 |